Explore Lightcast’s next-generation platform for single-cell functional analysis. Uncover detailed insights into cellular behaviour to accelerate research, drug discovery, and diagnostic development.
Location: England
Employees: 51-200
Total raised: $76M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 27.10.2025 | ND CAPITAL | nd.capital |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.04.2026 | - | $27M | Longwall V... |
| 22.08.2023 | Series B | $49M | - |
Mentions in press and media 5
| Date | Title | Description |
| 21.04.2026 | Lightcast Secures Major Funding, Redefines Single-Cell Analysis with Envisia Platform | Lightcast, a life science innovator, secured $27 million in funding. ARCH Venture Partners led the round. This capital fuels the 2026 commercial launch of its Envisia™ benchtop platform. Envisia marks a significant leap in single-cell analy... |
| 15.04.2026 | Lightcast Raises $27M in Funding | Lightcast, a Cambridge, UK-based life science tools company focused on functional single-cell analysis, raised $27M in funding. The round was led by ARCH Venture Partners with participation from M Ventures, Illumina Ventures, +ND Capital, L... |
| 14.04.2026 | Lightcast Raises $27 Million and Adds Industry Veteran to Accelerate Commercialization of Envisia™ Platform | · Proceeds will help enhance workflows and expand single-cell functional assay portfolio · Brad Crutchfield joins as advisor to support early access growth and global launch CAMBRIDGE, England – April 14, 2026 – Lightcast, a pioneering life... |
| 22.08.2023 | Lightcast Discovery secures $49 million in Series B financing to commercialize its single-cell platform for functional analysis | Cambridge, UK - Lightcast Discovery Ltd., a life science tools company developing a novel single-cell functional analysis platform, announces the completion of a £38M (c. $49 million) Series B funding round, led by M Ventures. Current inves... |
| 18.08.2023 | Lightcast Discovery Raises $49M in Series B Financing | Lightcast Discovery, a Cambridge, UK-based life science tools company developing a novel single-cell functional analysis platform, raised $49M in Series B funding. The round was led by M Ventures with participation from ARCH Venture Partner... |